In Situ Transfection by Controlled Release of Lipoplexes Using Acoustic Droplet Vaporization.
In Situ Transfection by Controlled Release of Lipoplexes Using Acoustic Droplet Vaporization.
复制标题
DOI:
10.1002/adhm.201600008
复制
发表时间:
2016-07
影响因子:
10
通讯作者:
Fabiilli ML
中科院分区:
文献类型:
--
作者:
Juliar BA;Bromley MM;Moncion A;Jones DC;O'Neill EG;Wilson CG;Franceschi RT;Fabiilli ML
Localized delivery of nucleic acids to target sites (e.g., diseased tissue) is critical for safe and efficacious gene therapy. An ultrasound-based technique termed acoustic droplet vaporization (ADV) has been used to spatiotemporally control the release of therapeutic small molecules and proteins contained within sonosensitive emulsions. Here, ADV was used to control the release of lipoplex – containing plasmid DNA with an enhanced green fluorescent protein (eGFP) reporter - from a sonosensitive emulsion. Focused ultrasound (3.5 MHz, mechanical index (MI) ≥ 1.5) generated robust release of fluorescein (i.e., surrogate payload) and lipoplex from the emulsion. In situ release of the lipoplex from the emulsion using ADV (MI=1.5, 30 cycles) yielded a 55% release efficiency, resulting in 43% transfection efficiency and 95% viability with C3H/10T1/2 cells. Without exposure to ultrasound, the release and transfection efficiencies were 5% and 7%, respectively, with 99% viability. Lipoplex released by ADV retained its bioactivity while the ADV process did not yield any measureable sonoporative enhancement of transfection. Co-encapsulation of Ficoll PM 400 within the lipoplex loaded emulsion, and its subsequent release using ADV, yielded higher transfection efficiency than the lipoplex alone. The results demonstrate that ADV could have utility in the spatiotemporal control of gene delivery.